 Artelo Biosciences, Inc. ARTL, a clinical stage biopharmaceutical company focused on developing proprietary therapeutics that target the endocannabinoid system and related biological signaling pathways, today announced that the U.S. Patent and Trademark Office has issued a composition of matter patent with claims covering ART12.11, the Companys cocrystal, solid form of CBD cannabidiol and TMP tetramethypyrazine. The new U.S. patent, No. 10,604467 for Solid Forms of Cannabidiol and Uses Thereof, provides intellectual property protection for ART12.11 until December 10, 2038. Artelos approach to achieving patent protection for a novel CBD composition was to create a cocrystal. 